NASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis $13.40 -0.17 (-1.25%) As of 10/23/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Syndax Pharmaceuticals Stock (NASDAQ:SNDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Syndax Pharmaceuticals alerts:Sign Up Key Stats Today's Range$13.20▼$13.6150-Day Range$12.90▼$20.7852-Week Range$12.80▼$25.59Volume4.25 million shsAverage Volume2.32 million shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/APrice Target$41.80Consensus RatingModerate Buy Company Overview Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment. Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children. The company is also associated with Niktimvo (axatilimab-csfr), a CSF-1 receptor antibody approved for certain adults with chronic graft-versus-host disease after inadequate response to at least two prior systemic therapies. Syndax is commercializing Niktimvo through a collaboration with Incyte. The company continues to advance a pipeline of investigational therapies intended to target cancer biology and immune-mediated diseases. Syndax is led by Michael A. Metzger, who serves as chief executive officer.AI Generated. May Contain Errors. Read More Syndax Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreSNDX MarketRank™: 2.82733716731 of 5 starsSyndax Pharmaceuticals scored higher than 57% of companies evaluated by MarketBeat, and ranked 403rd out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSyndax Pharmaceuticals has a consensus price target of $41.80, representing about 211.9% upside from its current price of $13.40.Amount of Analyst CoverageSyndax Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Syndax Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($2.01) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 18.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Syndax Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted21.62% of the float of Syndax Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 8.47.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently decreased by 11.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News SentimentSyndax Pharmaceuticals has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Syndax Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders4.80% of the stock of Syndax Pharmaceuticals is held by insiders.Percentage Held by InstitutionsSyndax Pharmaceuticals has minimal institutional ownership at this time.Read more about Syndax Pharmaceuticals' insider trading history. Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNDX Stock News HeadlinesSNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS LawOctober 17, 2026 | businesswire.comSyndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 ListOctober 16, 2026 | uk.finance.yahoo.com“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.October 24 at 1:00 AM | Weiss Ratings (Ad)Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 ListOctober 15, 2026 | globenewswire.comSyndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)October 13, 2026 | prnewswire.comSyndax Pharmaceuticals Selloff After IPF Trial Failure Appears 'Overdone,' BofA Securities SaysOctober 13, 2026 | marketscreener.comMSyndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionOctober 13, 2026 | benzinga.comSyndax Pharmaceuticals, Inc. Announces Topline Results From MAXPIRe Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary FibrosisOctober 13, 2026 | marketscreener.comMSee More Headlines SNDX Stock Analysis - Frequently Asked Questions How have SNDX shares performed this year? Syndax Pharmaceuticals' stock was trading at $21.01 at the beginning of the year. Since then, SNDX stock has decreased by 36.2% and is now trading at $13.40. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.10. Syndax Pharmaceuticals's quarterly revenue was up 91.8% on a year-over-year basis. Read the conference call transcript. When did Syndax Pharmaceuticals IPO? Syndax Pharmaceuticals (SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Top institutional investors of Syndax Pharmaceuticals include Inspire Investing LLC (0.04%) and Sterling Capital Management LLC. Insiders that own company stock include Michael A Metzger, Dennis Podlesak, Keith A Goldan, Neil Gallagher and Nicholas AJ Botwood. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Delta Air Lines (DAL), Walt Disney (DIS) and Verastem (VSTM). Company Calendar Last Earnings8/04/2026Today10/24/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 11 days, SNDX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SNDX CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees298Year Founded2005Price Target and Rating Average Price Target for Syndax Pharmaceuticals$41.80 High Price Target$57.00 Low Price Target$33.00 Potential Upside/Downside+211.9%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$285.42 million Net Margins-87.52% Pretax Margin-87.52% Return on Equity-372.94% Return on Assets-39.11% Debt Debt-to-Equity Ratio38.95 Current Ratio6.77 Quick Ratio6.44 Sales & Book Value Annual Sales$252.25 million Price / Sales4.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book18.11Miscellaneous Outstanding Shares88,610,000Free Float84,357,000Market Cap$1.19 billion OptionableOptionable Beta0.42 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:SNDX) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
